Search results for "Drug administration"

showing 10 items of 393 documents

Chronic lithium salt treatment reduces CRE/CREB-directed gene transcription and reverses its upregulation by chronic psychosocial stress in transgeni…

2007

The molecular mechanism of action of the mood stabilizer lithium is assumed to involve changes in gene expression leading to neuronal adaptation. The transcription factor CREB (cAMP-responsive element binding protein) regulates the expression of many genes and has been implicated in important brain functions and the action of psychogenic agents. We here investigated the effect of lithium on cAMP-responsive element (CRE)/CREB-mediated gene transcription in the brain, using transgenic reporter mice that express the luciferase reporter gene under the control of four copies of the rat somatostatin gene promoter CRE. Chronic (21 days) but not acute (24 h) treatment with lithium (7.5 mmol/kg) sig…

MaleTranscriptional ActivationBipolar DisorderTransgeneDown-RegulationMice TransgenicCREBDrug Administration Schedule03 medical and health sciencesGlycogen Synthase Kinase 3Mice0302 clinical medicineGSK-3Transcription (biology)Antimanic AgentsGenes ReporterGene expressionAnimalsPhosphorylationProtein kinase ACyclic AMP Response Element-Binding ProteinSocial BehaviorTranscription factor030304 developmental biologyPharmacology0303 health sciencesReporter genebiologyBehavior AnimalBrainMolecular biologyUp-RegulationPsychiatry and Mental healthDisease Models AnimalGene Expression RegulationChronic Diseasebiology.proteinLithium Compounds030217 neurology & neurosurgeryStress PsychologicalAdenylyl CyclasesSignal TransductionNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology
researchProduct

Local Delivery of Nimodipine by Prolonged-Release Microparticles—Feasibility, Effectiveness and Dose-Finding in Experimental Subarachnoid Hemorrhage

2012

Background and purposeTo investigate the effect of locally applied nimodipine prolonged-release microparticles on angiographic vasospasm and secondary brain injury after experimental subarachnoid hemorrhage (SAH).Methods70 male Wistar rats were categorized into three groups: 1) sham operated animals (control), 2) animals with SAH only (control) and the 3) treatment group. SAH was induced using the double hemorrhage model. The treatment group received different concentrations (20%, 30% or 40%) of nimodipine microparticles. Angiographic vasospasm was assessed 5 days later using digital subtraction angiography (DSA). Histological analysis of frozen sections was performed using H&E-staining as …

MaleVasodilator AgentsGene ExpressionPolylactic Acid-Polyglycolic Acid CopolymerVasospasm IntracranialDrug DistributionMultidisciplinarymedicine.diagnostic_testMicrofilament ProteinsQRBrainIntracranial ArteryVasospasmAnimal ModelsImmunohistochemistryHemorrhagic StrokeNeurologyAnesthesiaInjections IntravenousToxicityMedicinemedicine.symptomMicrotubule-Associated ProteinsResearch Articlemedicine.drugDrugs and DevicesDrug Research and DevelopmentSubarachnoid hemorrhageCerebrovascular DiseasesScienceNeurosurgeryBrain damageDrug Administration ScheduleModel OrganismsmedicineAnimalsPharmacokineticsLactic Acidcardiovascular diseasesRats WistarBiologyNimodipineDose-Response Relationship Drugbusiness.industryCalcium-Binding ProteinsAngiography Digital SubtractionDigital subtraction angiographySubarachnoid Hemorrhagemedicine.diseaseRatsnervous system diseasesDelayed-Action PreparationsAngiographyRatNimodipineSurgerybusinessPolyglycolic AcidPLoS ONE
researchProduct

Time to onset of bisphosphonate-related osteonecrosis of the jaws: a multicentre retrospective cohort study

2017

Objectives: Osteonecrosis of the jaw (ONJ) is a potentially severe adverse effect of bisphosphonates (BP). Although the risk of ONJ increases with increasing duration of BP treatment, there are currently no reliable estimates of the ONJ time to onset (TTO). The objective of this study was to estimate the TTO and associated risk factors in BP-treated patients. Subjects and Methods: Retrospective analysis of data from 22 secondary care centres in seven countries relevant to 349 patients who developed BP-related ONJ between 2004 and 2012. Results: The median (95%CI) TTO was 6.0 years in patients treated with alendronate (n = 88) and 2.2 years in those treated with zoledronate (n = 218). Multiv…

MalebisphosphonateTime Factorsmedicine.medical_treatmentOsteoporosis0302 clinical medicineRisk Factors80 and overosteoporosijaw osteonecrosiAged 80 and overBone Density Conservation AgentsDiphosphonatesjaw osteonecrosisjaw osteonecrosis bisphosphonates breast cancer multiple myeloma prostate cance osteoporosisIncidenceIncidence (epidemiology)Otorhinolaryngology2734 Pathology and Forensic MedicineMiddle Agedprostate cancermultiple myeloma030220 oncology & carcinogenesisBisphosphonate-Associated Osteonecrosis of the JawFemaleAdultmedicine.medical_specialty2734Drug Administration SchedulePathology and Forensic Medicine03 medical and health sciencesbreast cancerbisphosphonates; breast cancer; jaw osteonecrosis; multiple myeloma; osteoporosis; prostate cancer; Adult; Aged; Aged 80 and over; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Cross-Sectional Studies; Diphosphonates; Drug Administration Schedule; Female; Humans; Incidence; Male; Middle Aged; Multivariate Analysis; Proportional Hazards Models; Retrospective Studies; Risk Factors; Time Factors; Otorhinolaryngology; 2734; Pathology and Forensic Medicine; Dentistry (all)Internal medicinemedicineHumansBisphosphonates; Breast cancer; Jaw osteonecrosis; Multiple myeloma; Osteoporosis; Prostate cancer; Otorhinolaryngology2734 Pathology and Forensic Medicine; Dentistry (all)prostate canceAdverse effectGeneral DentistrybisphosphonatesAgedProportional Hazards ModelsRetrospective StudiesBisphosphonate-associated osteonecrosis of the jawbusiness.industryProportional hazards modelRetrospective cohort study030206 dentistryBisphosphonatemedicine.diseaseosteoporosisSurgeryCross-Sectional StudiesOtorhinolaryngologyMultivariate AnalysisDentistry (all)businessOsteonecrosis of the jaw
researchProduct

The use of opioids in the last week of life in an acute palliative care unit.

2010

The aim of this survey was to assess the opioid use in the last week of life of cancer patients admitted at an acute palliative care unit. From a consecutive sample of patients surveyed for a period of one year, patients who died in the unit were selected. Type of opioid, route of administration, and doses were recorded one week before death (or at admission time if the interval admission-death was less than one week) (-7), and on the day of death (Tend). Seventy-seven patients died in the unit in the period taken into consideration (12.4%). Oral morphine equivalents were 170 mg/day and 262 mg/day at -7 and Tend, respectively. Patients were receiving transdermal drugs or intravenous morphi…

Malecancer patientmedicine.medical_specialtyPalliative careUnit (housing)CONSECUTIVE SAMPLEIntravenous morphineNeoplasmsmedicineHumanssurveyIntensive care medicineAgedTerminal Careopioid useMorphinebusiness.industryDrug Administration RoutesOpioid usePalliative CareCancerGeneral MedicineMiddle Agedsurvey; opioid use; cancer patients; palliative caremedicine.diseaseDrug UtilizationAnalgesics OpioidItalyInjections IntravenousFemalebusiness
researchProduct

Effect of mesalazine on epithelial cell proliferation in colonic diverticular disease

2007

Background and aims: increased epithelial cell proliferation may be detected in diverticular disease, but antibiotics have failed in reducing it. We assess therefore the effect of mesalazine on epithelial cell proliferation in diverticular disease. Methods: a prospective study was conducted on 20 consecutive patients with a new endoscopic diagnosis of symptomatic uncomplicated diverticular disease. The patients were treated with mesalazine 1.6 mg/day for 1 year. The Ki-67 antigen index of the whole crypt and in the upper third was separately evaluated before and after starting the treatment. Results: cell proliferation index was higher in diverticular disease patients than healthy controls …

Malediverticular diseaseSeverity of Illness IndexGastroenterologychemistry.chemical_compoundReference ValuesProspective StudiesIntestinal MucosaMesalamineProspective cohort studyCell proliferationtreatmentmedicine.diagnostic_testAnti-Inflammatory Agents Non-SteroidalBiopsy Needledigestive oral and skin physiologyGastroenterologyColonoscopyMiddle AgedImmunohistochemistryDiverticulosisDose–response relationshipTreatment OutcomemesalazineDiverticular diseaseFemalemedicine.medical_specialtyCryptRisk Assessmentdigestive systemDrug Administration ScheduleStatistics NonparametricMesalazineInternal medicineBiopsyDiverticulosis ColonicmedicineHumansAgedProbabilityDose-Response Relationship DrugHepatologybusiness.industryCase-control studyEpithelial Cellsmedicine.diseasedigestive system diseasescolonic mucosaKi-67 AntigenchemistryCase-Control StudiesbusinessFollow-Up StudiesDigestive and Liver Disease
researchProduct

The rewarding effects of ethanol are modulated by binge eating of a high-fat diet during adolescence

2017

Abstract Binge-eating is considered a specific form of overeating characterized by intermittent and high caloric food intake in a short period of time. Epidemiologic studies support a positive relation between the ingestion of fat and ethanol (EtOH), specifically among adolescent subjects. The aim of this work was to clarify the role of the compulsive, limited and intermittent intake of a high-fat food during adolescence on the rewarding effects of EtOH. After binge-eating for 2 h, three days a week from postnatal day (PND) 29, the reinforcing effects of EtOH were tested with EtOH self-administration (SA), conditioned place preference (CPP) and ethanol locomotor sensitization procedures in …

Maleendocrine systemmedicine.medical_specialtyTime FactorsSelf AdministrationNucleus accumbensDiet High-FatMice03 medical and health sciencesCellular and Molecular Neuroscience0302 clinical medicineRewardInternal medicinemental disordersmedicineAnimalsIngestionBulimiaOvereatingreproductive and urinary physiologyPharmacologyEthanolBinge eatingDrug Administration RoutesCentral Nervous System DepressantsConditioned place preference030227 psychiatryVentral tegmental areaDisease Models Animalmedicine.anatomical_structureEndocrinologyAnimals NewbornAnesthesiaConditioning Operantmedicine.symptomμ-opioid receptorSelf-administrationPsychologyLocomotion030217 neurology & neurosurgeryNeuropharmacology
researchProduct

Early discharge and home treatment of patients with low-risk pulmonary embolism with the oral factor Xa inhibitor rivaroxaban: an international multi…

2020

Abstract Aims To investigate the efficacy and safety of early transition from hospital to ambulatory treatment in low-risk acute PE, using the oral factor Xa inhibitor rivaroxaban. Methods and results We conducted a prospective multicentre single-arm investigator initiated and academically sponsored management trial in patients with acute low-risk PE (EudraCT Identifier 2013-001657-28). Eligibility criteria included absence of (i) haemodynamic instability, (ii) right ventricular dysfunction or intracardiac thrombi, and (iii) serious comorbidities. Up to two nights of hospital stay were permitted. Rivaroxaban was given at the approved dose for PE for ≥3 months. The primary outcome was sympto…

Malehome treatmentpulmonary embolismrisk stratification030204 cardiovascular system & hematology0302 clinical medicineRivaroxabanRecurrenceRisk FactorsOutpatientsMedicineProspective StudiesRight ventricular dysfunctionEarly dischargeAged 80 and overeducation.field_of_studyHome treatmentriskinarviointiMiddle AgedEUROPEAN-SOCIETYPatient DischargeINPATIENT TREATMENT3. Good healthPulmonary embolismTreatment OutcomeHOSPITALIZATIONAmbulatoryright ventricular dysfunctionFemaleCardiology and Cardiovascular Medicinemedicine.drugAdultmedicine.medical_specialtyAdolescentmanagement trialpotilaan kotiuttaminenkotihoitoPopulationDrug Administration Schedule03 medical and health sciencesYoung AdultInternal medicineMANAGEMENTkliiniset kokeetHumansseurantaddc:610Home treatment; Management trial; Pulmonary embolism; Right ventricular dysfunction; Risk stratification; RivaroxabaneducationRisk stratificationAgedRivaroxabanbusiness.industryManagement trial030229 sport sciences3126 Surgery anesthesiology intensive care radiologymedicine.diseaseInterim analysisOUTPATIENT TREATMENTConfidence intervalhyytymisenestohoitoClinical trialTHROMBOSIS3121 General medicine internal medicine and other clinical medicinelääkehoitosydän- ja verisuonitauditveritulppabusinessPulmonary EmbolismFactor Xa InhibitorsEuropean heart journal
researchProduct

Immunogenicity of a combination vaccine containing diphtheria toxoid, tetanus toxoid, three-component acellular pertussis, hepatitis B, inactivated p…

2011

Two randomized trials of 13-valent pneumococcal conjugate vaccine (PCV13) relative to PCV7 evaluated the immune responses of coadministered antigens comprising Infanrix(®) hexa/Infanrix(®)-IPV+Hib (diphtheria, tetanus, 3-component acellular pertussis, hepatitis B, inactivated poliovirus, and Haemophilus influenzae type b). After the 3-dose infant series, immunogenic noninferiority was demonstrated for all concomitantly administered antigens between the PCV13 and PCV7 groups. All antigens elicited good booster responses after the toddler dose except pertussis toxoid; however, 99.6% subjects achieved pertussis toxoid protective antibody level ≥5EU/mL in both groups. These results support the …

Malemedicine.disease_causeAntibodies ViralDiphtheria-Tetanus-acellular Pertussis Vaccinescomplex mixturesPneumococcal conjugate vaccineDrug Administration SchedulePneumococcal VaccinesAntigenDouble-Blind MethodGermanymedicineHumansHepatitis B VaccinesVaccines CombinedDiphtheria-Tetanus-Pertussis VaccineHaemophilus VaccinesVaccines ConjugateGeneral VeterinaryGeneral Immunology and MicrobiologybiologyTetanusbusiness.industryDiphtheriaPoliovirusImmunogenicityPublic Health Environmental and Occupational HealthInfantHepatitis Bmedicine.diseaseVirologyAntibodies BacterialPoliovirus Vaccine InactivatedInfectious DiseasesTreatment OutcomeSpainbiology.proteinMolecular MedicineFemaleAntibodybusinessmedicine.drugVaccine
researchProduct

Antibiotic single-dose prophylaxis of shunt infections.

1989

Shunt infections after implantation or revision of a shunt for CSF drainage in hydrocephalic patients are serious complications. In view of their frequency, this study investigated the efficacy of prophylactic administration of a single dose of the antibiotic cefazedone in reducing in the post-operative infection rate. Fifty children of up to 14 years of age suffering from hydrocephalus of various etiologies were treated prophylactically and compared with a similar untreated group. The diagnosis of infection was based mainly on microbiological and clinical observations and investigations. Classical infection parameters were also recorded and evaluated, but played only a secondary role in es…

Malemedicine.medical_specialtyAdolescentmedicine.drug_classmedicine.medical_treatmentAntibioticsInfectionsDrug Administration ScheduleCefazedoneCefazolinmedicineHumansDerivationProspective StudiesChildChemotherapyInfection Controlbusiness.industryInfant NewbornInfantDrug Resistance MicrobialGeneral Medicinemedicine.diseaseCerebrospinal Fluid ShuntsHydrocephalusShunt (medical)SurgeryAnti-Bacterial AgentsAnesthesiaChild PreschoolSurgeryFemaleNeurology (clinical)NeurosurgeryComplicationbusinessmedicine.drugNeurosurgical review
researchProduct

Evaluation of an alternative dosing regimenwith tadalafil, three times per week, for men with erectile dysfunction: SURE study in Italy.

2007

AIM: To examine the preference for two dosing regimens of 20 mg of tadalafil, on demand or three times per week, in men affected with erectile dysfunction (ED) in Italy. METHODS: Scheduled Use versus on demand Regimen Evaluation (SURE) is a multicenter, crossover and open-label study, involving 94 urology centers in Italy. Patients aged 18 years or older affected with ED for at least 3 months were enrolled and randomized to 20 mg of tadalafil treatment on demand or three times per week for 5-6 weeks. After a 1-week washout, patients were crossed over to the alternate regimen for 5-6 weeks. A treatment preference question was used to determine the preferred treatment regimen. International I…

Malemedicine.medical_specialtyAlternate; Erectile dysfunction; On demand; SURE study; Tadalafil; Three times per week; Carbolines; Cross-Over Studies; Drug Administration Schedule; Erectile Dysfunction; Humans; Italy; Male; Middle Aged; Phosphodiesterase Inhibitors; Tadalafil; Treatment Outcome; Nephrology; EndocrinologyPhosphodiesterase Inhibitorserectile dysfunctionUrologyerectile dysfunction; SURE study; on demand; three times per week; alternate; tadalafilon demandDrug Administration Schedulelaw.inventionSettore MED/24 - UrologiaEndocrinologyRandomized controlled triallawOn demandInternal medicinealternateMedicineHumansClinical significanceDosingthree times per weekErectile dysfunction SURE Study on demand three times per week alternate tadalafilSURE studyCross-Over Studiesbusiness.industryGeneral MedicineMiddle Agedmedicine.diseaseCrossover studyTadalafilSurgeryRegimenErectile dysfunctionTreatment OutcomeItalyNephrologyAlternate; Erectile dysfunction; On demand; SURE study; Tadalafil; Three times per week; Carbolines; Cross-Over Studies; Drug Administration Schedule; Erectile Dysfunction; Humans; Italy; Male; Middle Aged; Phosphodiesterase Inhibitors; Tadalafil; Treatment Outcomebusinesstadalafilmedicine.drugCarbolines
researchProduct